Therapeutic Guidelines for treatment of tinea pedis updated
2 Sep 2024
In 2023, the Therapeutic Guidelines were updated to change the recommended treatment for tinea pedis of the foot, not between the toes. The Guidelines for tinea now state:
- Tinea is treated topically or systemically depending on its extent and location.
- Topical antifungal therapy is appropriate for recent onset of localised tinea affecting the trunk (including groin), limbs, face, or between the fingers or toes.
- Oral antifungal therapy is appropriate for tinea that:
- is widespread or established (particularly on the feet)
- has not responded to topical antifungal therapy
- recurs soon after treatment
- has been inappropriately treated with a topical corticosteroid
- is on the scalp, palms or soles
- is inflammatory, hyperkeratotic, vesicular or pustular.
With the recommended management available to endorsed podiatrists being either terbinafine 250mg (child less than 20 kg: 62.5 mg; child 20 to 40 kg: 125 mg) orally once daily for two weeks, or griseofulvin 500mg (child older than one month: 10 mg/kg up to 500 mg) orally once daily for 8-12 weeks. You may consider griseofulvin as it can be crushed and given with fatty food.
Further information for APodA members
To stay up to date with the latest news for endorsed prescribers, join our special interest group (SIG) for medicines in podiatry education, mentoring and knowledge sharing (for APodA members only).
Not yet a member? Please click here to sign up today.
Members, further details can be found on the Medicines in Podiatry (MIP) SIG group resource page here >>
<< Back to latest news